Company news
Oncolys BioPharma, Inc. news in 2026
Oncolys BioPharma, Inc.'s news releases, calls and decks from 2026, newest first.
Non-consolidated Financial Results for the Nine Months Ended September 30, 2026
November 6, 2026
Non-consolidated Financial Results for the Nine Months Ended September 30, 2026 [Japanese GAAP]
November 6, 2026
Non-consolidated Financial Results for the Six Months Ended June 30, 2026 [Japanese GAAP]
August 7, 2026
Oncolys BioPharma Announces Full Marketing Approval in Japan for Telomelysin for the Treatment of Esophageal Cancer
June 8, 2026
Oncolys BioPharma Announces Full Marketing Approval in Japan for Telomelysin for the Treatment of Esophageal Cancer
June 8, 2026
Non-consolidated Financial Results for the Three Months Ended March 31, 2026
May 8, 2026
Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2025
February 8, 2026